# Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

> **NCT07388550** · PHASE1 · NOT_YET_RECRUITING · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 15 (estimated)

## Conditions studied

- Post-Acute COVID-19 Syndrome

## Interventions

- **DRUG:** Keytruda

## Key facts

- **NCT ID:** NCT07388550
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-21
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07388550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07388550, "Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07388550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*